Talk Bio – Page 2 – Actionable Insights Powered by AI

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

1 day ago talkbio0Tagged China, License Agreement, Metabolic Diseases, milestone payments, Obesity, oral small-molecule therapeutics, OXTR gene, Partnership, royalties, strategic collaboration, upfront payment, Zealand Pharma

Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties

Health tech investors are getting creative with exits in 2025

1 day ago talkbio0Tagged 2025, AI healthtech IPOs, Exit, healthtech, Investments, M&A consolidation, Private Equity, provider operations, roll-ups, secondary markets, trends qualifier, Vital capacity

healthtech exits 2025; creative exit strategies; M&A consolidation; secondary markets; private equity roll-ups; AI healthtech IPOs; provider operations investment; VC healthtech trends

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

1 day ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, hormone receptor-positive, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, phase III lidERA trial, Recurrence Risk, Roche (company), San Antonio Breast Cancer Symposium

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Immunovant Announces Pricing of $550 Million Common Stock Financing

1 day ago talkbio0Tagged Capital, equity financing, financing characteristics, Immunovant, IMVT, IMVT-1402, Leerink Partners, Roivant Sciences

Immunovant; IMVT; common stock offering; $550 million financing; equity financing; underwritten offering; IMVT-1402; Roivant Sciences; Leerink Partners; biotech capital raise

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

1 day ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board

2 days ago talkbio0Tagged Advisory Board, AstraZeneca, Biological Science Disciplines, cancer drug development, Cancer Research Institute, DDX11-AS1 gene, executive appointments, Neoplasms, strategic advisory

Concr; AstraZeneca; Cancer Research Institute; advisory board; biotech; oncology; executive appointments; life sciences; strategic advisory; cancer drug development

Recent advances in AI for antimicrobial resistance (AMR) prevention and control

2 days ago talkbio0Tagged AI antibiotic discovery, Antibiotics, Antimicrobial Resistance, Diagnostics, Generative AI, GPR182 gene, Health care facility, Machine Learning, Phage Therapy, Stewardship, surveillance aspects

antimicrobial resistance; AI in healthcare; machine learning; antibiotic stewardship; AI antibiotic discovery; phage therapy; rapid diagnostics; AMR surveillance; generative AI

Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health

2 days ago talkbio0Tagged 2025, Accountability, AI-enabled, clinical oversight, digital health regulation, digital mental health devices, draft guidance, EU, EU AI Act health, Generative AI, Health care facility, Medical Devices, Regulation, Software as a Medical Device, United States Food and Drug Administration

AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices